



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 1 of 5

Effective Date: 7/5/2023 Last Review Date: 03/2023

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for extended-release opioid analgesics under the patient’s prescription drug benefit.

Description:

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines for extended-release opioid analgesics. The American Pain Society Opioid Treatment Guidelines state that a reasonable definition for high dose opioid therapy is greater than 200 mg daily of oral morphine (or equivalent). Requests to exceed these limits and those for any non-preferred product are subject to the criteria in this policy. Medications requested for more than 200 Morphine Milligram Equivalents (MME) per day will require a Medical Director Review.

Applicable Drug List:

Fentanyl Transdermal Patch
(Generic Duragesic)

Hydrocodone bitartrate 12 Hour ER Capsule
(Generic Zohydro ER)

Hydrocodone bitartrate 24 Hour ER Tablet
(Generic Hysingla ER)

Hydromorphone HCL 24 Hour ER Tablet
(Generic Exalgo)

Methadone HCL Tablet

Methadone HCL Oral Solution

Methadone HCL Oral Concentrate
(Generic Methadose)

Morphine Sulfate 12 Hour ER Tablet
(Generic MS Contin)



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 2 of 5

Effective Date: 7/5/2023 Last Review Date: 03/2023

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

Morphine Sulfate 24 Hour ER Capsule
(Generic Kadian)

Morphine Sulfate 24 hour ER Beads Capsule
(Generic Avinza)

Xtampza (oxycodone 12 Hour ER Capsule)

Oxycodone HCL 12 Hour ER Tablet
(Generic oxycontin)

Oxymorphone HCL 12 hour ER Tablet
(Generic Opana ER)

Nucynta ER (tapentadol HCL 12 hour ER Tablet)

Tramadol HCL 24 hour Biphasic Release Capsule
(Generic Conzip)

Tramadol HCL 24 Hour ER Tablet
(Generic Ultram ER)

Tramadol HCL 24 Hour Biphasic Release Tablet

Buprenorphine Transdermal Patch
(Generic Butrans)

Buprenorphine HCL Buccal Film
(Generic Belbuca)

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through hospice or palliative care
- AND**
- If the request is for a nonpreferred extended-release opioid analgesic, the patient is unable to take the required number of formulary alternatives for the given diagnosis



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Extended-Release Opioid Analgesics	Page:	3 of 5
Effective Date:	7/5/2023	Last Review Date:	03/2023
Applies to:	<input checked="" type="checkbox"/> Illinois <input type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Texas

due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

OR

- The requested drug is being prescribed for CHRONIC pain severe enough to require daily, around-the-clock, long-term treatment in a patient who has been taking an opioid [Note: Chronic pain is generally defined as pain that typically lasts greater than 3 months.]

AND

- The patient can safely take the requested dose based on their history of opioid use

AND

- The patient has been evaluated and the patient will be monitored regularly for the development of opioid use disorder

AND

- The patient's pain will be reassessed in the first month after the initial prescription or any dose increase AND every 3 months thereafter to ensure that clinically meaningful improvement in pain and function outweigh risks to patient safety

AND

- This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days **OR**

- The patient has taken an immediate-release opioid for at least one week

AND

- If the request is for a methadone product, then it is NOT being prescribed for detoxification treatment or as part of a maintenance treatment plan for opioid/substance abuse or addiction

AND

- If the request is for a nonpreferred extended-release opioid analgesic, the patient is unable to take the required number of formulary alternatives for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

[Note: These drugs should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.]

Quantity Limits may apply.

Approval Duration and Quantity Restrictions:

For pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through hospice or palliative care: Approve: 12 months



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Extended-Release Opioid Analgesics	Page:	4 of 5
Effective Date:	7/5/2023	Last Review Date:	03/2023
Applies to:	<input checked="" type="checkbox"/> Illinois <input type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Texas

For all other indications: Approve: 6 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Arymo ER [package insert]. Wayne, PA: Zyla Life Sciences US Inc.; October 2019.
2. Avinza [package insert]. New York, NY: Pfizer, Inc.; April 2014.
3. Belbuca [package insert]. Raleigh, NC: BioDelivery Sciences International, Inc.; March 2021.
4. Butrans [package insert]. Stamford, CT: Purdue Pharma L.P.; March 2021.
5. ConZip [package insert]. Bridgewater, NJ: Vertical Pharmaceuticals, Inc.; September 2021.
6. Dolophine Tablets [package insert]. Eatontown, NJ: West-Ward Pharmaceuticals Corp.; June 2021.
7. Duragesic [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2021.
8. Exalgo [package insert]. Webster Groves, MO: SpecGX LLC; June 2020.
9. Hysingla ER [package insert]. Stamford, CT: Purdue Pharma L.P.; March 2021.
10. Kadian [package insert]. Madison, NJ: Allergan USA, Inc.; October 2019.
11. Methadone Injection [package insert]. Morgantown, WV: Mylan Institutional LLC; June 2021.
12. Methadone Intensol Concentrate [package insert]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc.; April 2021.
13. Methadone Oral Solution [package insert]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc.; July 2020.
14. Methadone Tablets [package insert]. Mahwah, NJ: Glenmark Pharmaceuticals, Inc.; December 2019.
15. MorphaBond ER [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; October 2019.
16. MS Contin [package insert]. Stamford, CT: Rhodes Pharmaceuticals L.P.; March 2021.
17. Nucynta ER [package insert]. Stoughton, MA: Collegium Pharmaceutical, Inc; March 2021.
18. Opana ER [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; March 2021.
19. OxyContin [package insert]. Stamford, CT: Purdue Pharma L.P.; October 2021.
20. Targiniq ER [package insert]. Stamford, CT: Purdue Pharma L.P.; September 2018.
21. Tramadol extended-release capsules [package insert]. Los Angeles, CA: SA3, LLC; September 2018.
22. Tramadol extended-release tablets [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; June 2021.
23. Troxyca ER [package insert]. New York, NY: Pfizer, Inc.; December 2016.
24. Ultram ER [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2017.
25. Vantrela ER [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; January 2017.
26. Xtampza ER [package insert]. Cincinnati, OH: Patheon Pharmaceuticals; March 2021.
27. Zohydro ER [package insert]. Morristown, NJ: Currax Pharmaceuticals, LLC; March 2021.
28. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed December 2021.
29. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed December 2021.
30. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. *MMWR Recomm Rep*. 2016;65:1–49. Available at: <http://dx.doi.org/10.15585/mmwr.rr6501e1>. Accessed December 2021.
31. Palliative Care. NCCN Guidelines version 2.2021. Available at: http://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. Accessed December 2021.
32. Adult Cancer Pain. NCCN Guidelines version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed December 2021.
33. Chou R, Fanciullo G, Fine P, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. *The Journal of Pain*. 2009;10:113-130.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 5 of 5

Effective Date: 7/5/2023 Last Review Date: 03/2023

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

34. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Available at: https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf. Accessed December 2021.